

DAFTAR PUSTAKA

1. Muhadi. JNC 8 : Evidence-based Guideline Penanganan Pasien Hipertensi Dewasa. *Cermin Dunia Kedokt.* 2016;43(1):54–9.
2. Nurarif AH, Kusuma H. *Aplikasi Asuhan Keperawatan Berdasarkan Diagnosa Medis dan Nanda Nic-Noc.* Yogyakarta: Medication Publishing; 2015.
3. Sinubu RB, Rondonuwu R, Onibala F. Hubungan Beban Kerja dengan Kejadian Hipertensi Pada Tenaga Pengajar Di SMAN 1 Amurang Kabupaten Minahasa Selatan. *e-Journal Keperawatan.* 2015;3(2):1–8.
4. Kementerian Kesehatan Republik Indonesia. *Hipertensi Membunuh Diam-Diam Ketahui Tekanan Darah Anda.* Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.
5. Kementerian Kesehatan Republik Indonesia. *Sebagian Besar Penderita Hipertensi Tidak Menyadarinya.* Jakarta: Kementerian Kesehatan Republik Indonesia; 2017.
6. Kementerian Kesehatan Republik Indonesia. *Hasil Rikesdas 2018.* Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.
7. Martin J. *Hypertension Guidelines: Revitising The JNC 7 Recommendations.* Harrisburg: Lancaster, PA; 2009.
8. James PA. 2014 Evidence-based Guideline for the Management of High Blood Pressure in Adult: report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). American Medical Association: *JAMA*; 2013.
9. Michael, Devita Natalia, Santa Lin Margareta, Wurry Devian Putra CR, Gabrielia. *Tata Laksana Terkini pada Hipertensi.* *J Kedokt Meditek* [Internet]. 2014;20(52):36–41. Available from: ejournal.ukrida.ac.id/ojs/index.php/Ked/article/view/1012

10. Tjay TH. Obat-obat Penting. Jakarta: PT Elex Media Komputindo; 2015.
11. Ulfa NM. Analisis Efektivitas Kontrol Penurunan Tekanan Darah pada Pasien Hipertensi yang Mendapat Terapi Obat Antihipertensi Golongan Angiotensin Receptor Blocker's (Candesartan , Valsartan , Kalium Losartan). J Pharm Sci. 2017;2(2):9–14.
12. Farida U, Cahyani PW. Pola Penggunaan Obat Antihipertensi Pada Pasien Hipertensi Rawat Inap di RSUD Mardi Waluyo Blitar Bulan Juli-Desember Tahun 2016. J Wiyata. 2018;5(1):29–33.
13. Abraham HMA, White CM, White WB. The Comparative Efficacy and Safety of the Angiotensin Receptor Blockers in the Management of Hypertension and Other Cardiovascular Diseases. NIH Public Access. 2015;38(1):33–54.
14. Ardiansyah M. Medikal Bedah Untuk Mahasiswa. Yogyakarta: DIVA Press; 2012.
15. Hananta IPY, Freitag H. Deteksi Dini dan Pencegahan Hipertensi dan Stroke. Yogyakarta: MedPress; 2011.
16. Siti S. Buku Ajar Ilmu Penyakit Dalam. 6th ed. Jakarta: Interna Publishing; 2015.
17. Bope ET, Kellerman RD. Current Therapy. Philadelphia: Elsevier; 2017.
18. Kementerian Kesehatan Republik Indonesia. Hipertensi. Jakarta: Kementerian Kesehatan Republik Indonesia; 2016.
19. Fauzi I. Buku Pintar Deteksi Dini Gejala, & Pengobatan Asam Urat, Diabetes & Hipertensi. Yogyakarta: Araska; 2014.
20. Kowalak JP. Patofisiologi. Jakarta: EGC; 2011.
21. Riyadi S. Keperawatan Medikal Bedah. Yogyakarta: Pustaka Pelajar; 2011.

22. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL. Harrison's Principles of Internal Medicine. 16th ed. New York: McGraw-Hill Professional; 2004.
23. Yogiantoro M. Buku Ajar Ilmu Penyakit Dalam: Hipertensi Esensial. 5th ed. Jakarta: Interna Publishing; 2009.
24. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA - J Am Med Assoc.* 2014;311(5):507–20.
25. Zhang W, Si LY. Obstructive sleep apnea syndrome (OSAS) and hypertension: Pathogenic mechanisms and possible therapeutic approaches. *Ups J Med Sci.* 2012;117(4):370–82.
26. Al Sabbah Z, Mansoor A, Kaul U. Angiotensin Receptor Blockers - Advantages of the New Sartans. *J Assoc Physicians India.* 2013;61(7):464–70.
27. National Center for Biotechnology Information. PubChem Compound Summary for CID 3961, Losartan [Internet]. 2021 [cited 2021 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Losartan>
28. Siddiqui N, Husain A, Chaudhry L, Alam MS, Mitra M, Bhasin PS. Pharmacological and Pharmaceutical Profile of Valsartan: A Review. *J Appl Pharm Sci.* 2011;01(04):12–9.
29. Criscione L, de Gasparo M, Bühlmayer P, Whitebread S, Ramjoué HR, Wood J. Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. *Br J Pharmacol.* 1993;110(2):761–71.
30. Saydam M, Takka S. Bioavailability file : Valsartan. *Fabad J Pharm Sci.* 2007;32:185–96.

31. National Center for Biotechnology Information. PubChem Compound Summary for CID 3749, Irbesartan [Internet]. 2021 [cited 2021 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Irbesartan>
32. National Center for Biotechnology Information. PubChem Compound Summary for CID 2540, Candesartan cilexetil [Internet]. 2021 [cited 2021 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Candesartan-cilexetil>
33. Yamagishi S ichi, Nakamura K. Telmisartan, its potential therapeutic implications in cardiometabolic disorders. *Recent Pat Cardiovasc Drug Discov.* 2006;1(1):79–83.
34. National Center for Biotechnology Information. PubChem Compound Summary for CID 5281037, Eprosartan [Internet]. 2021 [cited 2021 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Eprosartan>
35. National Center for Biotechnology Information. PubChem Compound Summary for CID 158781, Olmesartan [Internet]. 2021 [cited 2021 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Olmesartan>
36. National Center for Biotechnology Information. PubChem Compound Summary for CID 135409642, Azilsartan medoxomil [Internet]. 2021 [cited 2021 Apr 28]. Available from: <https://pubchem.ncbi.nlm.nih.gov/compound/Azilsartan-medoxomil>
37. Wuryaningsih L. *Farmakologi Klinis 2*. Surabaya: Sandira; 2010.
38. Nugroho AE. *Farmakologi*. 5th ed. Yogyakarta: Pustaka Pelajar; 2015.